Phase 1, Double Blind, Randomized, Parallel-group, 3‑Arm, Single-dose, Comparative Pharmacokinetic Study Of Pf‑06410293 And Adalimumab Sourced From Us And Eu Administered To Healthy Male And Female Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2015
At a glance
- Drugs Adalimumab (Primary)
- Indications Immunological disorders; Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms REFLECTIONS B538-07
- Sponsors Pfizer
- 12 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 23 Dec 2014 According to ClinicalTrial.gov record, planned number of patients changed from 285 to 360.